Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 64Burkitt Lymphoma 10Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Carcinoma, Non-Small-Cell Lung 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Plasma Cell 3Lymphoma, Non-Hodgkin 3Smoldering Multiple Myeloma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Immunoglobulin Light-chain Amyloidosis 2Down Syndrome 2beta-Thalassemia 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thalassemia 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Plasmacytoma 1

Interventions

venetoclax 6ibrutinib 4pirtobrutinib 2Sirolimus 2Rituximab 2Mycophenolic Acid 2Cyclosporine 2Cyclophosphamide 2zanubrutinib 1pembrolizumab 1loncastuximab tesirine 1fludarabine phosphate 1carfilzomib 1acalabrutinib 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Rifaximin 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Etoposide 1Dexamethasone 1Cyclosporins 1Calcium Dobesilate 1CT-P10 1Busulfan 1Biopsy 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Dexamethasone × 30 days × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡